Randomized trial · people

Semaglutide pill: 15.1% weight loss at 68 weeks in OASIS 1

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a large 68-week placebo-controlled trial, a once-daily 50 mg semaglutide pill led to substantial weight loss in adults without diabetes, and stomach and gut side effects were common.

Kind
Randomized trial
Studied in
People
Number studied
667
Published
2023
Journal
Lancet

What they tested

Does a daily 50 mg semaglutide pill lower body weight more than placebo in adults with overweight or obesity who do not have type 2 diabetes?

How the study was done

A randomized, double-blind, placebo-controlled phase 3 trial in 667 adults without type 2 diabetes, run at 50 clinics in Asia, Europe, and North America. To join, people needed a BMI of 30 kg/m2 or higher, or 27 kg/m2 or higher plus weight-related health problems. They took oral semaglutide, stepped up to 50 mg, or a look-alike dummy pill (placebo) once a day for 68 weeks, along with a lifestyle program.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 68 weeks, average body weight fell by 15.1% in the oral semaglutide 50 mg group and by 2.4% in the placebo group, a gap of 12.7 percentage points. A weight loss of at least 5% was reached by 85% of the semaglutide group and 26% of the placebo group, and a loss of at least 20% by 34% versus 3%. Side effects of any kind affected 92% on semaglutide and 86% on placebo. Stomach and gut side effects, mostly mild to moderate, affected 80% on semaglutide and 46% on placebo.

What it doesn’t show

Only one daily dose was tested, given with a lifestyle program, in adults who did not have type 2 diabetes, and follow-up stopped at 68 weeks; use beyond that point and people with diabetes fall outside what this trial covers. Novo Nordisk funded the trial.

The paper

Knop et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023.

The compounds

More studies on Semaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo